The uplift to this year's GP contract will 'significantly challenge' the ability of practices to maintain services, the president of the Primary Care Pharmacy Association (PCPA) has told The Pharmacist.
The 2024/25 GP contract arrangements, unveiled by NHS England last week, set out a 2.23% increase in funding for general practice – an increase in investment of £259m taking overall contract investment to £1,186m.
From this, all staff employed directly by practices will get a 2% pay increase, and the total funding for staff employed under the Additional Roles Reimbursement Scheme (ARRS) will also be increased by 2%.
But Dr Graham Stretch, PCPA president and a pharmacist partner in a GP surgery, told The Pharmacist that the increase was ‘well below inflationary pressures’ and suggested it would ‘significantly challenge practices’ ability to maintain services and (non-ARRS) staffing’.
‘Pharmacists in primary care continue to practice in a difficult financial situation,’ Dr Stretch added.
And he wished both the GP negotiator the British Medical Association General Practitioners Committee (BMA GPC) and the community pharmacy negotiator Community Pharmacy England (CPE) well in their negotiations with the Department of Health and Social Care (DHSC) going forwards.
Meanwhile, Paul Day, director of the Pharmacists' Defence Association (PDA), said: 'Like all areas of the NHS, the government need to fund GP practice properly so that pharmacists and other health professionals are practicing in suitably resourced clinical settings and receiving pay rates which retain or improve their real terms value.'
He added: 'GP practice is not immune to recruitment and retention issues and we know from surveying PDA members that pharmacists in any sector may be thinking of moving to a new role.'
The contractual arrangements also removed 'all caps' on the number of ‘direct patient care roles’ and advanced clinical practitioners (ACPs) that each PCN can recruit, within their funding envelope.
A new role of ‘enhanced nurses’ has also been added to the ARRS, while NHS England has confirmed that ARRS funding will not be spent on GPs as they are ‘not [an] additional’ role.
Have your say
Please add your comment in the box below. You can include links, but HTML is not permitted. Please note that comments are not moderated before publication and the views expressed are those of the user and do not reflect the views of The Pharmacist. Remember that submission of comments is governed by our Terms and Conditions. You can also read our full guidelines on article comments here – but please be aware that you are legally liable for any libellous or offensive comments that you make. If you have a complaint about a comment or are concerned that a comment breaches our terms and conditions, please use the ‘Report this comment’ function to alert our web team.